Cover Image

Association of HER2 overexpression and prognosis in small (T1N0) primary breast cancers

Background: There is some controversy regarding the precise role and need for adjuvant therapy in patients with pT1a/pT1bN0 breast cancer, although studies have indicated that a HER2-positive status is one of the most powerful poor prognostic factors. Patients and Methods: We retrospectively evaluat...

Full description

Saved in:
Bibliographic Details
Main Authors: Rom, Joachim (Author) , Schumacher, Claudia (Author) , Gluz, Oleg (Author) , Höfler, Josef (Author) , Eidt, Sebastian (Author) , Domschke, Christoph (Author) , Marmé, Frederik (Author) , Nitz, Ulrike (Author) , Sohn, Christof (Author) , Schneeweiss, Andreas (Author)
Format: Article (Journal)
Language:English
Published: June 22, 2013
In: Breast care
Year: 2013, Volume: 8, Issue: 3, Pages: 208-214
ISSN:1661-3805
DOI:10.1159/000352094
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000352094
Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/352094
Get full text
Author Notes:Joachim Rom, Claudia Schumacher, Oleg Gluz, Josef Höfler, Sebastian Eidt, Christoph Domschke, Frederik Marmé, Ulrike Nitz, Christof Sohn, Andreas Schneeweiss
Description
Summary:Background: There is some controversy regarding the precise role and need for adjuvant therapy in patients with pT1a/pT1bN0 breast cancer, although studies have indicated that a HER2-positive status is one of the most powerful poor prognostic factors. Patients and Methods: We retrospectively evaluated disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS) among 960 patients diagnosed between 2000 and 2008 with T1N0 primary breast cancer treated at 3 German centers, and determined prognostic risk factors. Univariate analysis was used to determine associations with potential risk factors. Results: With a median follow-up of 23 months, DFS was 94.8%, DDFS 96.3%, and OS 97.5%. Risk factors for decreased 1-year DFS were: peritumoral lymphatic invasion (L1) (p = 0.031), negative hormone receptor status (p = 0.003), non-use of hormonal therapy (p = 0.001), and a positive HER2 status (p = 0.003). Amongst the HER2-positive patients only 2.7% (n = 1/37) of those treated with trastuzumab had a DFS event compared with 20% (n = 10/50) without trastuzumab. Conclusion: Patients with HER2-positive T1 breast cancer should be considered for inclusion in prospective trials of trastuzumab in combination with chemotherapy to determine the risk-to-benefit ratio and association with other prognostic factors.
Item Description:Gesehen am 19.01.2022
Physical Description:Online Resource
ISSN:1661-3805
DOI:10.1159/000352094

Similar Items